Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial
-
Published:2023-11-08
Issue:1
Volume:18
Page:
-
ISSN:1748-717X
-
Container-title:Radiation Oncology
-
language:en
-
Short-container-title:Radiat Oncol
Author:
Kovacs Boldizsar,Mayinger Michael,Ehrbar Stefanie,Fesslmeier Debra,Ahmadsei Maiwand,Sazgary Lorraine,Manka Robert,Alkadhi Hatem,Ruschitzka Frank,Duru Firat,Papachristofilou Alexandros,Sticherling Christian,Blamek Slawomir,Gołba Krzysztof S.,Guckenberger Matthias,Saguner Ardan M.,Andratschke Nicolaus
Abstract
Abstract
Background
Stereotactic arrhythmia radioablation (STAR) is delivered with a planning target volume (PTV) prescription dose of 25 Gy, mostly to the surrounding 75–85% isodose line. This means that the average and maximum dose received by the target is less than 35 Gy, which is the minimum threshold required to create a homogenous transmural fibrosis. Similar to catheter ablation, the primary objective of STAR should be transmural fibrosis to prevent heterogenous intracardiac conduction velocities and the occurrence of sustained ventricular arrhythmias (sVA) caused by reentry. We hypothesize that the current dose prescription used in STAR is inadequate for the long-term prevention of sVA and that a significant increase in dose is necessary to induce transmural scar formation.
Objective
A single arm, multi-center, phase II, dose escalation prospective clinical trial employing the i3 + 3 design is being conducted to examine the safety of a radiation dose-escalation strategy aimed at inducing transmural scar formation. The ultimate objective of this trial is to decrease the likelihood of sVA recurrence in patients at risk.
Methods
Patients with ischemic or non-ischemic cardiomyopathy and recurrent sVA, with an ICD and history of ≥ 1 catheter ablation for sVA will be included. This is a prospective, multicenter, one-arm, dose-escalation trial utilizing the i3 + 3 design, a modified 3 + 3 specifically created to overcome limitations in traditional dose-finding studies. A total of 15 patients will be recruited. The trial aims to escalate the ITV dose from 27.0 Gy to an ITV prescription dose-equivalent level of maximum 35.1 Gy by keeping the PTV prescription dose constant at 25 Gy while increasing the dose to the target (i.e. the VT substrate without PTV margin) by step-wise reduction of the prescribing isodose line (85% down to 65%). The primary outcome of this trial is safety measured by registered radiation associated adverse events (AE) up to 90 days after study intervention including radiation associated serious adverse events graded as at least 4 or 5 according to CTCAE v5, radiation pneumonitis or pericarditis requiring hospitalization and decrease in LVEF ≥ 10% as assessed by echocardiography or cardiac MRI at 90 days after STAR. The sample size was determined assuming an acceptable primary outcome event rate of 20%. Secondary outcomes include sVA burden at 6 months after STAR, time to first sVA recurrence, reduction in appropriate ICD therapies, the need for escalation of antiarrhythmic drugs, non-radiation associated safety and patient reported outcome measures such as SF-36 and EQ5D.
Discussion
DEFT-STAR is an innovative prospective phase II trial that aims to evaluate the optimal radiation dose for STAR in patients with therapy-refractory sVA. The trial has obtained IRB approval and focuses on determining the safe and effective radiation dose to be employed in the STAR procedure.
Trial registration
NCT05594368.
Funder
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung Horizon 2020
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference22 articles.
1. WHO. Cardiovascular Disease Statistics 2019. 2. European Cardiovascular. Disease Statistics 2017. 3. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M, Cikes M, Kirchhof P, Abdelhamid M, Aboyans V, Arbelo E, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of Sudden Cardiac Death. Eur Heart J. 2022;43:3997–4126. 4. Al-khatib SM, Ackerman MJ, Gillis AM, Bryant WJ, Hlatky MA, Callans DJ, Granger CB, Curtis AB, Hammill SC, Kay GN, Field ME. AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2017;2017:1–186. 5. Ravi V, Poudyal A, Khanal S, Khalil C, Vij A, Sanders D, Larsen T, Trohman RG, Aksu T, Tung R, Santangeli P, Winterfield J, Sharma PS, Huang HD. A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies. J Interv Card Electrophysiol Springer US; 2022.
|
|